CAMBRIDGE, Mass., Oct. 1 /PRNewswire-FirstCall/ -- Idenix
Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company
engaged in the discovery and development of drugs for the treatment
of human viral diseases, today announced that three abstracts have
been accepted for presentation at the 61st Annual Meeting of the
American Association for the Study of Liver Diseases (AASLD,
October 29-November 2, 2010 in
Boston, Massachusetts). The
abstracts being presented are on three of the company's hepatitis C
clinical programs: IDX184, IDX320 and IDX375. Full abstracts can
now be viewed at the AASLD website at www.aasld.org.
The accepted abstracts are as follows:
- Lalezari, et al, "A Phase IIa Study of IDX184 in
Combination with Pegylated Interferon (PegIFN) and Ribavirin (RBV)
in Treatment-Naïve HCV Genotype 1-Infected Subjects" will be
featured as an oral presentation on Sunday,
October 31st at 3:45
p.m.
- Reesink, et al, "Antiviral Activity, Safety and
Pharmacokinetics of IDX320, a Novel Macrocyclic HCV Protease
Inhibitor, in a 3-Day Proof-of-Concept Study in Patients with
Chronic Hepatitis C" will be presented in a late-breaking
poster session on Monday, November
1st between 8:00 a.m. –
5:30 p.m.
- Bruijne, et al, "Phase I Study in Healthy Volunteers and
Patients with IDX375, a Novel Non-Nucleoside HCV Polymerase
Inhibitor" will be presented in a poster session on
Tuesday, November 2nd between
7:00 a.m. – 12:00 p.m.
About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a
biopharmaceutical company engaged in the discovery and development
of drugs for the treatment of human viral diseases. Idenix's
current focus is on the treatment of infections caused by hepatitis
C virus. For further information about Idenix, please refer to
www.idenix.com.
Forward-looking Statements
This press release contains "forward-looking statements" for
purposes of the safe harbor provisions of The Private Securities
Litigation Reform Act of 1995, including but not limited to the
statements regarding the company's future business and financial
performance. For this purpose, any statements contained herein that
are not statements of historical fact may be deemed forward-looking
statements. Without limiting the foregoing, the words "expect,"
"plans," "anticipates," "will," "expects," "goal," "estimates,"
"projects," "would," "could," "targets," and similar expressions
are also intended to identify forward-looking statements, as are
expressed or implied statements with respect to the company's
clinical development programs or commercialization activities in
hepatitis C, or any potential pipeline candidates, including any
expressed or implied statements regarding the efficacy and safety
of our drug candidates, the likelihood and success of any future
clinical trials involving our drug candidates or successful
development of novel combinations of direct-acting antivirals for
the treatment of hepatitis C. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of risks and uncertainties, including but not limited to the
following: there can be no guarantees that the company will advance
any clinical product candidate or other component of its potential
pipeline to the clinic, to the regulatory process or to
commercialization; management's expectations could be affected by
unexpected regulatory actions or delays, including the current
clinical hold on IDX184 and IDX320; uncertainties relating to, or
unsuccessful results of, clinical trials, including additional data
relating to the ongoing clinical trials evaluating its product
candidates; the company's ability to obtain additional funding
required to conduct its research, development and commercialization
activities; the company's dependence on its collaborations with
Novartis Pharma AG and GlaxoSmithKline; changes in the company's
business plan or objectives; the ability of the company to attract
and retain qualified personnel; competition in general; and the
company's ability to obtain, maintain and enforce patent and other
intellectual property protection for its product candidates and its
discoveries. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results to be materially different from any future results,
performance or achievements expressed or implied by such
statements. These and other risks which may impact management's
expectations are described in greater detail under the heading
"Risk Factors" in each of the company's annual report on Form 10-K
for the year ended December 31, 2009
and quarterly report on form 10-Q for the quarter ended
June 30, 2010, as filed with the
Securities and Exchange Commission (SEC) and in any subsequent
periodic or current report that the company files with the SEC.
All forward-looking statements reflect the company's estimates
only as of the date of this release (unless another date is
indicated) and should not be relied upon as reflecting the
company's views, expectations or beliefs at any date subsequent to
the date of this release. While Idenix may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so, even if the
company's estimates change.
|
|
Idenix Pharmaceuticals
Contact:
|
|
Jonae Barnes (617) 224-4485
(investors)
|
|
Kelly Barry (617) 995-9033
(media)
|
|
|
|
|
SOURCE Idenix Pharmaceuticals, Inc.
Copyright t. 1 PR Newswire